Company Description
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.
It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E.
coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E.
coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation.
In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.
It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
| Country | United States |
| Founded | 1982 |
| IPO Date | Apr 30, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | P. F. Te Boekhorst |
Contact Details
Address: 56 Evergreen Drive Portland, Maine 04103 United States | |
| Phone | 207 878 2770 |
| Website | immucell.com |
Stock Details
| Ticker Symbol | ICCC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000811641 |
| CUSIP Number | 452525306 |
| ISIN Number | US4525253062 |
| Employer ID | 01-0382980 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| P. F. Olivier Te Boekhorst | President, Chief Executive Officer and Director |
| Bobbi Jo Brockmann | Senior Vice President of Sales and Marketing |
| Timothy C. Fiori | Chief Financial Officer, Secretary, Treasurer and Director |
| Elizabeth S. Toothaker | Director of Finance and Administration and Controller |
| A. Gustavo Scaffa | Senior Director of Quality |
| John W. Zinckgraf | Director of Product Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 14, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 14, 2026 | 8-K | Current Report |
| Apr 8, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 10-K | Annual Report |
| Mar 18, 2026 | 8-K | Current Report |
| Mar 4, 2026 | 8-K | Current Report |
| Feb 9, 2026 | 8-K | Current Report |
| Feb 2, 2026 | 8-K | Current Report |
| Jan 8, 2026 | 8-K | Current Report |